The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma

Bradley A. McGregor(Harvard University), Joaquim Bellmunt(Dana-Farber Cancer Institute), Charlene Mantia(Dana-Farber Cancer Institute), H. Hvidsten(Harvard University), Praful Ravi(Dana-Farber Cancer Institute), Lucia Kwak(Harvard University), Xiao X. Wei(Dana-Farber Cancer Institute), Guru Sonpavde(AdventHealth Orlando), Toni K. Choueiri(Harvard University), J.E. Berchuck(Brigham and Women's Hospital), Stephanie Berg(Loyola University Medical Center), Meredith M. Regan(Dana-Farber Cancer Institute), Xīn Gào(Qingdao University), M. Dror Michaelson(Harvard University)
Annals of Oncology
October 21, 2023
10.1016/j.annonc.2023.09.3114
Cited by 94

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
|Cell|2017|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k